Page 36 - Read Online

Page 18 of 19 Khokhar et al. Mini-invasive Surg 2022;6:2 https://dx.doi.org/10.20517/2574-1225.2021.97

105. Castriota F, Nerla R, Micari A, Squeri A, Cremonesi A. Contrast-zero transcatheter aortic valve replacement for patients with severe
renal dysfunction: a single-center experience. JACC Cardiovasc Interv 2018;11:820-2. DOI PubMed
106. Huded CP, Tuzcu EM, Krishnaswamy A, et al. Association between transcatheter aortic valve replacement and early postprocedural
stroke. JAMA 2019;321:2306-15. DOI PubMed PMC
107. Kapadia SR, Huded CP, Kodali SK, et al; PARTNER Trial Investigators. Stroke after surgical versus transfemoral transcatheter aortic
valve replacement in the PARTNER trial. J Am Coll Cardiol 2018;72:2415-26. DOI PubMed
108. Pagnesi M, Martino EA, Chiarito M, et al. Silent cerebral injury after transcatheter aortic valve implantation and the preventive role
of embolic protection devices: a systematic review and meta-analysis. Int J Cardiol 2016;221:97-106. DOI PubMed
109. Spaziano M, Francese DP, Leon MB, Généreux P. Imaging and functional testing to assess clinical and subclinical neurological
events after transcatheter or surgical aortic valve replacement: a comprehensive review. J Am Coll Cardiol 2014;64:1950-63. DOI
PubMed
110. Kahlert P, Al-Rashid F, Döttger P, et al. Cerebral embolization during transcatheter aortic valve implantation: a transcranial Doppler
study. Circulation 2012;126:1245-55. DOI PubMed
111. Van Mieghem NM, Schipper ME, Ladich E, et al. Histopathology of embolic debris captured during transcatheter aortic valve
replacement. Circulation 2013;127:2194-201. DOI PubMed
112. Stachon P, Kaier K, Heidt T, et al. The use and outcomes of cerebral protection devices for patients undergoing transfemoral
transcatheter aortic valve replacement in clinical practice. JACC Cardiovasc Interv 2021;14:161-8. DOI PubMed
113. Butala NM, Makkar R, Secemsky EA, et al. Cerebral embolic protection and outcomes of transcatheter aortic valve replacement:
results from the transcatheter valve therapy registry. Circulation 2021;143:2229-40. DOI PubMed PMC
114. Latib A, Mangieri A, Vezzulli P, et al. First-in-man study evaluating the Emblok embolic protection system during transcatheter
aortic valve replacement. JACC Cardiovasc Interv 2020;13:860-8. DOI PubMed
115. Ahmad Y, Howard JP. Meta-analysis of usefulness of cerebral embolic protection during transcatheter aortic valve implantation. Am
J Cardiol 2021;146:69-73. DOI PubMed PMC
116. Kapadia SR, Krishnaswamy A. Cerebral embolic protection in transcatheter aortic valve replacement: connecting intuition and proof.
JACC Cardiovasc Interv 2021;14:169-71. DOI PubMed
117. Bagur R, Solo K, Alghofaili S, et al. Cerebral embolic protection devices during transcatheter aortic valve implantation: systematic
review and meta-analysis. Stroke 2017;48:1306-15. DOI PubMed
118. Seeger J, Gonska B, Otto M, Rottbauer W, Wöhrle J. Cerebral embolic protection during transcatheter aortic valve replacement
significantly reduces death and stroke compared with unprotected procedures. JACC Cardiovasc Interv 2017;10:2297-303. DOI
PubMed
119. Testa L, Latib A, Casenghi M, Gorla R, Colombo A, Bedogni F. Cerebral Protection during transcatheter aortic valve implantation:
an updated systematic review and meta-analysis. J Am Heart Assoc 2018;7:e008463. DOI PubMed PMC
120. Coughlan JJ, Fleck R, O’Connor C, Crean P. Mechanical thrombectomy of embolised native aortic valve post-TAVI. BMJ Case Rep
2017;2017:bcr2016218787. DOI PubMed PMC
121. D’Anna L, Demir O, Banerjee S, Malik I. Intravenous thrombolysis and mechanical thrombectomy in patients with stroke after
TAVI: a report of two cases. J Stroke Cerebrovasc Dis 2019;28:104277. DOI PubMed
122. Muntané-Carol G, Urena M, Munoz-Garcia A, et al. Late cerebrovascular events following transcatheter aortic valve replacement.
JACC Cardiovasc Interv 2020;13:872-81. DOI PubMed
123. Mangieri A, Montalto C, Poletti E, et al. Thrombotic versus bleeding risk after transcatheter aortic valve replacement: JACC review
topic of the week. J Am Coll Cardiol 2019;74:2088-101. DOI PubMed
124. Baumgartner H, Falk V, Bax JJ, et al; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of
valvular heart disease. Eur Heart J 2017;38:2739-91. DOI PubMed
125. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of
patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines. J Am Coll Cardiol 2017;70:252-89. DOI PubMed
126. Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic
valves: an observational study. Lancet 2017;389:2383-92. DOI PubMed
127. Backer O, Dangas GD, Jilaihawi H, et al; GALILEO-4D Investigators. Reduced leaflet motion after transcatheter aortic-valve
replacement. N Engl J Med 2020;382:130-9. DOI PubMed
128. Rosendael PJ, Delgado V, Bax JJ. Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-
generation devices: a systematic review. Eur Heart J 2018;39:2003-13. DOI PubMed
129. Sammour Y, Krishnaswamy A, Kumar A, et al. Incidence, predictors, and implications of permanent pacemaker requirement after
transcatheter aortic valve replacement. JACC Cardiovasc Interv 2021;14:115-34. DOI PubMed
130. Auffret V, Puri R, Urena M, et al. Conduction disturbances after transcatheter aortic valve replacement: current status and future
perspectives. Circulation 2017;136:1049-69. DOI PubMed
131. Mangieri A, Lanzillo G, Bertoldi L, et al. Predictors of advanced conduction disturbances requiring a late (≥48 h) permanent
pacemaker following transcatheter aortic valve replacement. JACC Cardiovasc Interv 2018;11:1519-26. DOI PubMed
132. Mauri V, Reimann A, Stern D, et al. Predictors of permanent pacemaker implantation after transcatheter aortic valve replacement
with the SAPIEN 3. JACC Cardiovasc Interv 2016;9:2200-9. DOI PubMed
133. Latsios G, Gerckens U, Buellesfeld L, et al. “Device landing zone” calcification, assessed by MSCT, as a predictive factor for
pacemaker implantation after TAVI. Catheter Cardiovasc Interv 2010;76:431-9. DOI PubMed